March 27, 2024, 2:50 a.m. | Dr. Tony Hoang

The Artificial Intelligence Podcast linktr.ee

Nvidia, a prominent artificial intelligence technology company, showcases interest in healthcare through launching new AI tools and partnering with Johnson & Johnson and GE Healthcare at its 2024 GTC conference. The adoption of AI in drug discovery speeds up the process while reducing costs. Nvidia's BioNeMo platform targets drug development and offers cost savings beyond that area. The company has invested $50 million in Recursion Pharmaceuticals and partnered with Roche's Genentech, Schrödinger, and others for medication development and treatment protocol …

adoption ai in drug discovery ai tools artificial artificial intelligence artificial intelligence technology bionemo conference costs development discovery drug development drug discovery ge healthcare gtc gtc conference healthcare intelligence nvidia partnerships platform process targets technology through tools

More from linktr.ee / The Artificial Intelligence Podcast

Data Architect

@ University of Texas at Austin | Austin, TX

Data ETL Engineer

@ University of Texas at Austin | Austin, TX

Lead GNSS Data Scientist

@ Lurra Systems | Melbourne

Senior Machine Learning Engineer (MLOps)

@ Promaton | Remote, Europe

Reporting & Data Analytics Lead (Sizewell C)

@ EDF | London, GB

Data Analyst

@ Notable | San Mateo, CA